vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Shutterstock, Inc. (SSTK). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $220.2M, roughly 1.1× Shutterstock, Inc.). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -7.3%, a 18.4% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -12.0%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $25.9M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 1.4%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Shutterstock, Inc. is an American provider of stock photography, stock footage, stock music, and editing tools; it is headquartered in New York. Founded in 2002 by programmer and photographer Jon Oringer, Shutterstock maintains a library of around 200 million royalty-free stock photos, vector graphics, and illustrations, with around 10 million video clips and music tracks available for licensing. Originally a subscription site only, Shutterstock expanded beyond subscriptions into à la carte p...
ANIP vs SSTK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $220.2M |
| Net Profit | $27.5M | $-16.0M |
| Gross Margin | — | 55.8% |
| Operating Margin | 14.1% | -1.1% |
| Net Margin | 11.1% | -7.3% |
| Revenue YoY | 29.6% | -12.0% |
| Net Profit YoY | 367.5% | -1021.0% |
| EPS (diluted) | $1.14 | $-0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $220.2M | ||
| Q3 25 | $227.8M | $260.1M | ||
| Q2 25 | $211.4M | $267.0M | ||
| Q1 25 | $197.1M | $242.6M | ||
| Q4 24 | $190.6M | $250.3M | ||
| Q3 24 | $148.3M | $250.6M | ||
| Q2 24 | $138.0M | $220.1M | ||
| Q1 24 | $137.4M | $214.3M |
| Q4 25 | $27.5M | $-16.0M | ||
| Q3 25 | $26.6M | $13.4M | ||
| Q2 25 | $8.5M | $29.4M | ||
| Q1 25 | $15.7M | $18.7M | ||
| Q4 24 | $-10.3M | $-1.4M | ||
| Q3 24 | $-24.2M | $17.6M | ||
| Q2 24 | $-2.3M | $3.6M | ||
| Q1 24 | $18.2M | $16.1M |
| Q4 25 | — | 55.8% | ||
| Q3 25 | — | 60.6% | ||
| Q2 25 | — | 60.3% | ||
| Q1 25 | — | 58.4% | ||
| Q4 24 | — | 55.1% | ||
| Q3 24 | — | 58.3% | ||
| Q2 24 | — | 58.5% | ||
| Q1 24 | — | 58.8% |
| Q4 25 | 14.1% | -1.1% | ||
| Q3 25 | 15.9% | 12.5% | ||
| Q2 25 | 6.6% | 13.0% | ||
| Q1 25 | 13.3% | 4.2% | ||
| Q4 24 | -2.3% | 5.3% | ||
| Q3 24 | -13.8% | 7.2% | ||
| Q2 24 | 3.7% | 9.4% | ||
| Q1 24 | 14.8% | 7.8% |
| Q4 25 | 11.1% | -7.3% | ||
| Q3 25 | 11.7% | 5.1% | ||
| Q2 25 | 4.0% | 11.0% | ||
| Q1 25 | 8.0% | 7.7% | ||
| Q4 24 | -5.4% | -0.6% | ||
| Q3 24 | -16.3% | 7.0% | ||
| Q2 24 | -1.7% | 1.6% | ||
| Q1 24 | 13.2% | 7.5% |
| Q4 25 | $1.14 | $-0.47 | ||
| Q3 25 | $1.13 | $0.37 | ||
| Q2 25 | $0.36 | $0.82 | ||
| Q1 25 | $0.69 | $0.53 | ||
| Q4 24 | $-0.45 | $-0.04 | ||
| Q3 24 | $-1.27 | $0.50 | ||
| Q2 24 | $-0.14 | $0.10 | ||
| Q1 24 | $0.82 | $0.45 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $178.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $581.0M |
| Total Assets | $1.4B | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $178.2M | ||
| Q3 25 | $262.6M | $165.5M | ||
| Q2 25 | $217.8M | $116.4M | ||
| Q1 25 | $149.8M | $112.2M | ||
| Q4 24 | $144.9M | $111.3M | ||
| Q3 24 | $145.0M | $131.4M | ||
| Q2 24 | $240.1M | $74.9M | ||
| Q1 24 | $228.6M | $71.8M |
| Q4 25 | $540.7M | $581.0M | ||
| Q3 25 | $505.8M | $594.4M | ||
| Q2 25 | $436.8M | $586.2M | ||
| Q1 25 | $418.6M | $547.2M | ||
| Q4 24 | $403.7M | $518.4M | ||
| Q3 24 | $405.9M | $522.9M | ||
| Q2 24 | $455.8M | $520.4M | ||
| Q1 24 | $452.0M | $541.3M |
| Q4 25 | $1.4B | $1.4B | ||
| Q3 25 | $1.4B | $1.4B | ||
| Q2 25 | $1.3B | $1.4B | ||
| Q1 25 | $1.3B | $1.3B | ||
| Q4 24 | $1.3B | $1.3B | ||
| Q3 24 | $1.3B | $1.3B | ||
| Q2 24 | $920.8M | $1.0B | ||
| Q1 24 | $914.5M | $1.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $36.2M |
| Free Cash FlowOCF − Capex | $29.1M | $25.9M |
| FCF MarginFCF / Revenue | 11.8% | 11.8% |
| Capex IntensityCapex / Revenue | 0.5% | 4.7% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $123.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $36.2M | ||
| Q3 25 | $44.1M | $78.4M | ||
| Q2 25 | $75.8M | $26.8M | ||
| Q1 25 | $35.0M | $25.2M | ||
| Q4 24 | $15.9M | $8.0M | ||
| Q3 24 | $12.5M | $-11.6M | ||
| Q2 24 | $17.4M | $28.0M | ||
| Q1 24 | $18.3M | $8.3M |
| Q4 25 | $29.1M | $25.9M | ||
| Q3 25 | $38.0M | $68.0M | ||
| Q2 25 | $71.8M | $15.5M | ||
| Q1 25 | $32.5M | $14.4M | ||
| Q4 24 | $13.5M | $-952.0K | ||
| Q3 24 | $7.7M | $-26.3M | ||
| Q2 24 | $13.0M | $18.9M | ||
| Q1 24 | $13.7M | $-6.2M |
| Q4 25 | 11.8% | 11.8% | ||
| Q3 25 | 16.7% | 26.1% | ||
| Q2 25 | 34.0% | 5.8% | ||
| Q1 25 | 16.5% | 6.0% | ||
| Q4 24 | 7.1% | -0.4% | ||
| Q3 24 | 5.2% | -10.5% | ||
| Q2 24 | 9.4% | 8.6% | ||
| Q1 24 | 10.0% | -2.9% |
| Q4 25 | 0.5% | 4.7% | ||
| Q3 25 | 2.7% | 4.0% | ||
| Q2 25 | 1.9% | 4.2% | ||
| Q1 25 | 1.3% | 4.5% | ||
| Q4 24 | 1.3% | 3.6% | ||
| Q3 24 | 3.2% | 5.9% | ||
| Q2 24 | 3.2% | 4.1% | ||
| Q1 24 | 3.3% | 6.7% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | 5.86× | ||
| Q2 25 | 8.87× | 0.91× | ||
| Q1 25 | 2.23× | 1.35× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -0.66× | ||
| Q2 24 | — | 7.71× | ||
| Q1 24 | 1.00× | 0.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
SSTK
Segment breakdown not available.
